Melanoma, Nevogenesis, and Stem Cell Biology  by Grichnik, James M.
Melanoma, Nevogenesis, and Stem Cell Biology
James M. Grichnik1
It is now well established that a subpopulation of tumor stem cells (TSCs) are present within cancer tissues. This
suggests that tumors evolve from stem cells; however, the exact cell of tumor origin, the potential role
of dedifferentiation, and the role of plasticity in tumor development are largely unknown. A model cancer for
the study of the oncologic process is melanoma. The developmental biology of melanocytes is relatively well
understood, the cells pigment as they differentiate making them easy to identify, and benign and malignant
tumors develop on the skin surface allowing direct observation of growth features, early detection, and
removal. This ready access to early-stage tumors will facilitate study of the early oncologic processes and the
role of tissue stem cells. Melanomas, like other cancers, include a subpopulation of TSCs. These TSCs have
access to embryologic developmental programs, including the capacity to differentiate along multiple cell
lineages. For example, melanomas can activate germ–cell pathways with major implications for TSC self-renewal
through the activation of telomerase and genomic instability through the collision of meiotic and mitotic
pathways (meiomitosis). The TSC model is still evolving, but the existence of TSCs has significant ramifications
for tumor development, diagnosis, prognosis, and treatment of melanoma and other cancers.
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Introduction
Cancer development, progression, and
therapeutics remain at the forefront of
medical research. The recognition of a
subpopulation of tumor stem cells
(TSCs) in solid cancers has reinvigo-
rated the field. These cells have the
capacity to self-renew and give rise to
more differentiated cell forms (Reya
et al., 2001). The existence of these
TSCs implicates a pluripotent stem cell
as the cell of origin for cancer. How-
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PERSPECTIVE
Editor’s Note
Malignant melanoma has long been identified as one of the
most important and inscrutable of all skin diseases. In his
1941 review DeCholnoky concluded ‘‘Radical surgery is
the treatment of choice, and should consist of wide local
excision... followed by regional lymph node dissection....’’
While the recommended extent of surgery may have
decreased over the last 60+ years, it is remarkable that
our knowledge of the basic biology of malignant melano-
ma has not resulted in significant changes in treatment;
indeed, metastatic melanoma remains one of the malig-
nancies most resistant to treatment. In the next two issues
of the JID, recent advances in our understanding of the
biology of malignant melanoma are featured. In this issue,
Grichnik discusses how melanoma stem cells may play a
critical role in the pathogenesis of melanoma and its
resistance to conventional therapy. Zaidi and co-workers
explore the role of UV light in the pathogenesis of
melanoma and how animal models can advance our
understanding of both initiation and metastasis. Next
month, Hocker and co-workers review recent advances
in the genetics of melanoma and how they may lead to
new specific therapeutic interventions. Finally, Fang and
co-workers discuss how recent advances in immunology
have resulted in new strategies for using the immune
system to treat life-threatening metastatic disease. In 1930
Dr James Ewing wrote, ‘‘The problems of melanoma
maintain their position as the most interesting and complex
of any department of oncology..... Possibly there are other
important data lying within easy reach of the alert
observer.’’ While the ‘‘problems of melanoma’’ persist,
these Perspectives demonstrate the significant progress and
challenges that characterize our understanding of melanoma
in the 21st century; I hope they will present new directions
for study by the ‘‘alert observer’’.
Russell P. Hall, III, Deputy Editor
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ever, ‘‘dedifferentiation’’ from a mature
tissue cell has not been completely
excluded. Although the cell of origin
can still be questioned, there is no
doubt that the TSCs exist and play a
critical role in tumor maintenance.
TSCs, although only a small fraction
of the tumor bulk, have been shown to
be the cells with the capacity to give
rise to new tumor nodules. Tumori-
genic (TSCs) versus non-tumorigenic
populations were initially defined in
hematologic malignancies (Lapidot
et al., 1994; Bonnet and Dick, 1997)
and have recently been identified in
breast (Al-Hajj et al., 2003), pancreatic
(Li et al., 2007), colon (Dalerba et al.,
2007; O’Brien et al., 2007; Ricci-
Vitiani et al., 2007), squamous cell
(Prince et al., 2007), brain (Singh et al.,
2003; Kondo et al., 2004), and lung
cancers (Ho et al., 2007). TSC popula-
tions have also been shown to be able
to differentiate along multiple cell
lineages; for example, in glioma,
TSCs have been shown to differentiate
along both the neural and glial path-
ways (Kondo et al., 2004). The findings
suggest that TSCs have access to
embryologic developmental programs,
including the capacity to differentiate
along multiple cell lineages.
Melanoma, like other cancers, in-
cludes a subpopulation of TSCs. The
tumor often visibly develops on the
surface of the skin, and with the advent
of dermoscopy, and developing
technologies such as confocal micro-
scopy, the early development of
these lesions will be able to be better
studied. In addition to the malignant
lesions, benign nevi also develop on
the skin surface and may provide
additional critical information about
the role of tissue stem cells and/or
mature melanocytes in the early stages
of tumor evolution. The relatively
well-defined developmental biology of
melanocytes, as well as the ready
access to normal and diseased tissue,
makes melanoma a model system for
the study of stem cell biology and
carcinogenesis. Tumorigenesis is now
best viewed as an aberrant develop-
mental process. This review examines
selected aspects of normal embryologic
and melanocytic development, home-
ostasis, nevogenesis, and tumorgenesis,
as they may apply to melanocytic TSC
biology.
Normal embryologic development
The fertilized egg is the ultimate
‘‘stem cell’’. During cell division, the
protoplasm is asymmetrically distribu-
ted due to the influence of cellular and
extracellular signal gradients. As cell
numbers expand and the cells are
exposed to local environmental signals,
selective differentiation occurs and a
vast array of tissue structures is formed.
During the cellular developmental pro-
cess, nuclear DNA is modified (altera-
tion of histones and DNA methylation)
and segregated within the nuclear
matrix structure controlling gene ex-
pression and cell fate.
The developing cell is dependent on
accurate DNA primary sequence, and
therefore DNA mutations are actively
identified and repaired. If mutations
cannot be repaired, the cell is depen-
dent on the intact apoptotic pathways
for elimination, as otherwise a mosaic
disorder would develop. Once a defec-
tive cell has been eliminated, its posi-
tion in the developmental gradient will
be occupied by a neighboring cell,
which will differentiate appropriately
as long as it has sufficient plasticity.
Early embryonic cells have remarkable
plasticity as up to one-fourth of the
8-cell embryo can be removed without
appreciable long-term sequella (Hardy
et al., 1990; Pierce et al., 1997). With
further development, the degree of
plasticity retained by cells is most likely
to be dependent on its ultimate func-
tion. Some cells would be expected not
to maintain the capacity to differentiate
along other cell lineages. Obvious
examples would include cells in which
the nucleus has been reabsorbed such
as red blood cells or corneocytes, cells
that have undergone meiotic events
such as egg or sperm cells, or cells in
which DNA recombination has occur-
red such as T and B immunoregulatory
cells. However, to sustain and repair
tissue, a considerable number of cells
must maintain significant plasticity into
adulthood. Presumably, these cells are
retained as specialized tissue stem
cells, but it is possible that some well-
differentiated cells retain intrinsic plas-
ticity. The fact that some cell nuclei can
be used in cloning experiments suggests
that nuclear changes in some cells are
sufficiently reversible to generate a new
embryo (Oback and Wells, 2007).
The human developmental process
proceeds quite quickly, and within 9
months a single cell gives rise to more
than a trillion individual cells with a
total mass of more than 3 kg. This
cellular mass is elegantly organized,
including a multitude of different cell
types appropriately interacting with
tightly controlled proliferation/apopto-
tic and mitotic/meiotic mechanisms,
with the capacity and plasticity to grow
and repair tissues for about a century. A
TSC inherently has access to all these
capacities.
Embryonic development of melanocytes
Melanocytic cells appear to be primar-
ily derived from the developing neural
crest. The migration of the neural crest
has been elegantly studied through the
utilization of a reporter system that
labels cells with an activated dopa-
chrome tautomerase (DCT) promoter,
which is expressed in melanocytic and
neural progenitors (Mackenzie et al.,
1997; Jiao et al., 2006). In the murine
system, melanocytic precursor cells can
be first recognized in the neural crest at
approximately embryonic day 8.5,
these cells migrate between the derma-
tome and the overlying ectoderm
in the dorsolateral pathway, migration
continues ventrally through the devel-
oping dermis at day 10.5, the cells
begin to insert into the epidermis and
the developing hair follicles at day
14.5, these cells proliferate and differ-
entiate with pigment synthesis observed
around postnatal day 4 (Wilkie et al.,
2002).
The melanocytic developmental pro-
cess is very dependent on stem cell
factor (SCF) and its receptor, KIT. Dis-
tinct waves of SCF/KIT dependence and
independence play a role in melanocyte
survival, migration, and epidermal in-
sertion (Nishikawa et al., 1991; Okura
et al., 1995; Yoshida et al., 1996). These
waves of KIT dependence and indepen-
dence are also seen during the hair
cycle (Nishikawa et al., 1991). In
addition, endothelin 3 (ET-3) and the
endothelin B receptor play a critical role
in melanocyte development, as loss of
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these pathways also results in the loss of
cutaneous melanocytes (Baynash et al.,
1994; Hosoda et al., 1994). A number of
other cytokine pathways have also been
documented to play a role, including
a-melanocyte stimulating hormone,
basic fibroblast growth factor (bFGF),
nerve growth factor, endothelin 1,
granulocyte macrophage-colony stimu-
lating factor, and hepatocyte growth
factor (for review see Halaban, 2000;
Hirobe, 2005).
Melanocytic development can also
be driven in vitro through the use of
embryonic stem cells (ESC). Using
mouse ESCs cultivated on a feeder
layer of ST2 cells, dexamethasone was
noted to induce the formation of
melanocytes (Yamane et al., 1999).
Inhibition of the KIT pathway (with
ACK2) blocked melanocyte produc-
tion, whereas the addition of ET3
enhanced the number of melanocytic
cells. Another group noted that the
addition of retinoic acid to the ESC
culture increased the production of
melanocytes (Motohashi et al., 2007).
KITþ cells developed were isolated by
cell sorting and were shown to be
multipotent with the capacity to give
rise to melanocytes, glia, and neurons.
The development of melanocytes could
be antagonized by an ET-3 inhibitor
(BQ788). A third group has demon-
strated the need for Wnt3a for the
development of melanocytes in their
ESC system (Fang et al., 2006). In the
presence of WNT3a and ET-3, melano-
cytes could be produced. Melanocyte
production was further augmented by
the addition of SCF.
Thus, there is a well-orchestrated set
of events within the embryonic mass
that exposes embryonic cells to the
appropriate factors to differentiate
the proper number of melanocytes in
the correct location. Theoretically, this
specific series of developmental expo-
sures reorganizes the DNA nuclear
matrix to initiate the appropriate ex-
pression of melanocytic genes. The
melanocytic differentiation process
can also be induced in vitro by expos-
ing ESCs to the appropriate cytokines,
potentially allowing a more straightfor-
ward study of nuclear changes.
Although this melanocytic develop-
mental process is normally driven by
external environmental signals, it is
most likely that the internal abnormal
activation of intracellular signaling
pathways, such as the activation of B-
Raf, in a stem cell could also drive
melanocytic differentiation.
Adult melanocytes
Melanocytes integrate into the epider-
mis and function to provide melanin as
a UV protectant to neighboring kerati-
nocytes. The melanocytes may also
perform other functions, including en-
docrine (Slominski et al., 2007; Takeda
et al., 2007), metal chelation (Farmer
et al., 2003; Meyskens et al., 2004;
Hong and Simon, 2007), and immune
functions, yet to be fully explored
(Burkhart and Burkhart, 2005). In per-
forming these duties, the melanocyte is
susceptible to UV and oxidative stress,
which may create genetic mutations.
Ideally, damaged melanocytes would
be eliminated. Although normal mela-
nocytic turnover is generally impercep-
tible, melanocytes being discharged
through the epidermis (‘‘pagetoid’’
melanocytes) can be seen after acute
sun exposure, over nevi, and melano-
mas (Pharis and Zitelli, 2001; Petronic-
Rosic et al., 2004).
The number of melanocytes in the
epidermis is tightly controlled and this
is primarily due to their interaction with
local keratinocytes. A major homeo-
static factor in the adult skin is SCF.
Epidermal keratinocytes produce SCF
in both a membrane bound and soluble
form, but local fibroblasts may also
contribute to SCF levels. SCF/KIT sti-
mulation or inhibition has been shown
to drive proliferation or loss, respec-
tively, of melanocytes in human skin
(Grichnik et al., 1995, 1998). Expres-
sion of SCF in the mouse epidermis
results in the retention of melanocytes
when they would have otherwise been
lost (Kunisada et al., 1998). Signaling
through SCF/KIT and other pathways
provides the homeostatic signaling to
maintain the appropriate number of
epidermal melanocytes in adult skin.
Melanocytes can be cultured from
isolated epidermal sheets. Multiple
growth factors or chemical stimulants
are necessary to promote and maintain
melanocyte proliferation in vitro (Ha-
laban, 2000). The response of the cells
to SCF in vitro can be modulated, with
SCF functioning as a survival factor
under low bFGF conditions, a prolif-
erative factor with intermediate levels
of bFGF, but having no additional
proliferative effect over bFGF when
high levels of bFGF are present (Lin
et al., 2000). Thus, the homeostatic role
of SCF can be partially recapitulated
in vitro.
Melanocytes obtained from neonatal
foreskins grow robustly while melano-
cytes from older human skin samples
grow poorly. Eventually, melanocytes
will senesce in culture (Bennett and
Medrano, 2002). This suggests that these
epidermal melanocyte cultures either do
not include a stem cell component or
the existing culture conditions do not
promote or maintain melanocytic stem
cells. However, the melanocytes in
culture may have some plasticity, as
‘‘fibroblast’’ outgrowth is not uncom-
mon in melanocyte cultures. Although
this is assumed to be due to contamina-
tion, it is possible that these cells are
derived from melanocytic precursors.
As the human ages, the capacity to
make and retain melanocytic cells
appears to diminish. The most obvious
example of this is the graying of
hair. Although this loss of melanocytes
is generally considered permanent,
it is interesting to note that there are
case reports describing spontaneous
hair repigmentation (Etienne et al.,
2002; Kavak et al., 2005).
Thus, epidermal melanocytes
clearly play a critical role in UV
protection. As a consequence of this
function, these cells may be particu-
larly susceptible to mutation and need
to be regularly turned over to prevent
the accumulation of damaged DNA.
Presumably, these damaged cells are
discharged through the epidermis. The
number of epidermal melanocytes is
tightly controlled by local factors. With
aging, the total number of melanocytes
gradually diminishes.
Stem cell populations in adult skin
Melanocytes, like cells in many other
tissues, are turned over and replenished
from immature precursors. Disease
processes such as vitiligo give us a
window into this process. In active
vitiligo, differentiated melanocytes are
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destroyed. During recovery, new mel-
anocytes migrate into the epidermis
from a protected population of cells
(Figure 1). A similar phenomenon can
be driven experimentally in zebrafish.
Treatment with 4-(4-morpholinobu-
tylthio)phenol results in the death of
differentiated melanocytes, and these
cells are replaced by cells derived from
a precursor population (Yang and
Johnson, 2006). Thus, differentiated
melanocytes are replaced by cells that
differentiate from an immature precur-
sor population.
A major reservoir for melanocytic
precursors is the hair follicle. Precursor
cells have been identified in this loca-
tion through the expression of KIT
(Grichnik et al., 1996). These cells also
expressed Bcl-2, which may play a role
in the survival of the stem cell compart-
ment, because mice defective for
Bcl-2 loose melanocytic stem cells
(Nishimura et al., 2005). Melanocyte
isolation from the hair follicle has
revealed the presence of heavily pig-
mented mature and amelanotic imma-
ture cell populations (Na et al., 2006).
Consistent with stem cell biology, the
amelanotic population was shown to
have a slower doubling rate but en-
hanced a long-term proliferation capa-
city compared with the pigmented cell
population. With age and graying of
the hair, residual melanocytic stem cell
populations have been noted to be
decreased (Nishimura et al., 2005).
The melanocytic stem cell compart-
ment in the murine hair follicle has
been studied using a DCT reporter
system to identify the melanocytic
lineage cells (Nishimura et al., 2002).
These cells gave rise to transiently
amplifying (TA) population of melano-
cytes that populated the hair bulb;
however, some of the cells were able
to return to a quiescent state in the hair
bulge area. KIT receptor expression
appears to be downregulated in a
quiescent subpopulation but upregu-
lated on migratory melanocytic cells
during the hair cycle (Botchkareva
et al., 2001; Peters et al., 2002). In
the quiescent cells, although a few
pathways were upregulated including
the Notch pathway, there appeared to
be a global suppression of transcrip-
tion, including decreased expression of
melanocytic genes (Nishikawa and
Osawa, 2007). At the end of each hair
cycle, differentiated melanocytes in
the hair bulb are presumed to undergo
apoptosis (Tobin et al., 1998).
It would be easier to model the stem
cell system if it were only unidirec-
tional. However, the capacity for a TA
cell to become a quiescent stem cell
suggests that some degree of dediffer-
entiation is possible. A dramatic exam-
ple of the potential for a melanocyte
to dedifferentiate in vitro has been
demonstrated in the quail system
(Real et al., 2006; Dupin et al., 2007).
Quail skin melanocytes have been
shown to give rise to Sox-10, Pax3,
and slug-expressing stem cells. Further-
more, the stem cells were pluripotent,
that is they had the capacity to give rise
to glia, myofibroblasts, and melano-
cytes. Because stem cells are present in
the skin, the extent to which melano-
cyte dedifferentiation occurs in vivo is
unclear but clearly the potential exists.
Stem cells are present in normal
skin. A number of groups have focused
on epidermal stem cells and their role
in giving rise to keratinocytes (Bick-
enbach and Grinnell, 2004; Blanpain
and Fuchs, 2006; Cotsarelis, 2006). The
seven groups presented below have
examined skin stem cell populations
capable of producing melanocytes and/
or other neural crest derivatives.
One group isolated a cell population
of small size and low Hoechst 33342
staining from green fluorescence pro-
tein (GFP)-labeled murine epidermis
and injected the GFPþ cells into
blastocysts. They were able to show
that the GFPþ cells gave rise to
ectodermal, mesenchymal, and neural
crest-derived tissues (Liang and Bick-
enbach, 2002).
A second group isolated cells from
human hair follicles in conditioned
human embryonic stem cell media
(Yu et al., 2006). These ‘‘hair follicle
stem cells’’ were noted to express
nestin, slug, snail, twist, sox-9, and
bmp4. Focal Nanog and Oct4, a toti-
potent embryonic stem and germ cells
marker, expressions were also noted.
This group was able to differentiate
these cells into melanocytes, neuronal,
and smooth muscle cells.
A third group using a nestin-GFP
construct was able to isolate cells from
the bulge area of the murine hair
follicle (Amoh et al., 2005). The GFPþ
cells were found to be CD34þ and
keratin 15. They were able to differ-
entiate these cells into keratinocytes,
melanocytes, neurons, glia, and
smooth muscle cells. In vivo, the
formation of blood vessels and neural
tissue was shown. The ability to gen-
erate melanocytes and keratinocytes
from the same bulge stem cell popula-
tion is quite intriguing.
A fourth group identified sphere-
forming cells from skin culture (the
epidermis and the dermis) that were
Figure 1. Repigmentation during recovery from vitiligo. During the active phase of vitiligo, cutaneous
melanocytes are destroyed. During recovery, as seen in this clinical image of a patient’s leg (a), the
destroyed melanocytic cells can be replaced. These new melanocytes appear to be derived from a
protected population of cells within the hair follicle as shown in these dermoscopic images (b and c) from
two patients recovering from vitiligo.
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noted to express P75 and Sox-10
(Wong et al., 2006). These cells also
produced multiple lineages but not
keratinocytes. With the addition of
SCF and ET-3, they were able to induce
the formation of a few melanocytes. It
was noted that the skin from the face
produced spheres with more potential,
whereas spheres formed from the trunk
skin grew less copiously and were
more restricted in their cell production
yielding only glial and melanocytic
lineages. A further experiment utilized
a murine line with GFP expression in
cells in which the DCT promoter
was active. These mice made GFPþ
spheres that lacked pigmented melano-
cytes, suggesting that the DCT promo-
ter was active in p75 and Sox-10-
positive stem cells.
A fifth group has isolated multipotent
stem cells that they term ‘‘skin-derived
precursors’’ (SKPs) from the rodent skin
(Toma et al., 2001). The SKPs were
derived from the dermis, but could not
be derived from the epidermis, and
were found to express nestin and
fibronectin but not vimentin or cytoker-
atin. The SKPs were shown to differ-
entiate into neurons, glia, smooth
muscle, and adipocytes. A similar po-
pulation of cells from the adult human
scalp skin was also derived (Toma et al.,
2001). Further work on these SKPs has
revealed that they also express snail/
slug, twist, and Pax3 (Fernandes et al.,
2004). Based on localization of
expressed markers, they suggest a major
niche for the SKPs is in the dermal
papilla rather than in the hair bulge.
A sixth group attempted to
determine the molecular signature of
‘‘neural crest epidermal stem cells’’
(EPI-NCSC) isolated from the hair bulge
area (Hu et al., 2006). Nestin protein
expression was present in 2- to 7-day
culture with KIT expression present at
day 5. At day 7, autonomic neurons,
Schwann cells, melanocytes, bone/
cartilage cells, and myofibroblasts could
be identified. EPI-NCSCs were defined
as the cells emigrating from hair bulge
murine whisker while in culture. The
gene pattern of the EPI-NCSC cells (day
2 in culture) was shown to be different
than that of the epidermal stem cells
(Tumbar et al., 2004) and the stem cells
that may be increased in the dermal
papilla (Toma et al., 2001; Fernandes
et al., 2004). Their work suggests at
least three different stem cell popula-
tions may be present in the skin.
A seventh group has identified
CD133þ (also Thy-1þ and CD34 low)
cells in human skin. These multipotent
stem cells have the capacity to differ-
entiate into neurons, astrocytes, and
oligodendrocytes (Belicchi et al.,
2004). The CD133þ cells constitute
about 6% fetal skin cells but are only
about 1% of adult cells. Cell prolifera-
tion and plasticity was more attenuated
in adult cells than in the fetal counter
parts. These cells expressed c-kit and
CD34 (by reverse transcription-PCR)
(Belicchi et al., 2004). CD133þ cells
have also been previously noted in the
human epidermis (Yu et al., 2002) and
in a subpopulation of cells in cultures
human foreskin melanocytes (Frank
et al., 2003).
The CD133þ cells are particularly
interesting, as they have been noted to
identify neural crest stem cells (Uchida
et al., 2000), endothelia precursor cells
(Gehling et al., 2000), and mast cell
precursor cells (Dahl et al., 2002). In
bone marrow transplantation experi-
ments, the precursors for mast cells
have been noted to insert into the hair
follicle (Kumamoto et al., 2003).
Although difficult to comprehend given
our current models, it is possible that
both melanocytes and mast cells are
replenished from a common circulating
CD133þ precursor. Furthermore, it is
possible that these are the cells respon-
sible for the spontaneous repigmenta-
tion of gray hair.
Thus, the skin contains cells with
stem cell characteristics, and many of
these defined populations have the
proven capacity to give rise to melano-
cytes and/or at neural crest lineage cell
populations. Although it could be
argued that, in some of these experi-
ments, the cells dedifferentiated from a
more mature precursor, clearly in
others, the stem cells expressed mar-
kers defining them as present prior to
culture manipulation. The interrelation-
ships between these different stem cell
populations, their differentiation state
in tissue, and the extent to which the
differences experimental techniques
modify the cells have yet to be fully
defined. However, it is clear that
there are several potential stem cell
populations in human skin with the
capacity to give rise to melanocytes. It
is even possible that melanocytes could
be replenished from a circulating
CD133þ pluripotent precursor.
Nevogenesis
Origin and direction of melanocytic
nevus growth. Nevi are benign clonal
proliferations of cells expressing the
melanocytic phenotype (Robinson
et al., 1998; Hui et al., 2001). In
congenital nevi, it is presumed that a
precursor cell is mutated, possibly by
the activation of N-Ras (Bauer et al.,
2007), and an excessive number of
daughter cells result. The migrating
cells populate subcutaneous, dermal,
and epidermal structures, as they at-
tempt to complete normal migration to
the skin surface. Some of the excess
melanocytes completing migration may
be discharged through the epidermis as
‘‘pagetoid’’ cells in early congenital
nevi (Figure 2). Transepidermal elimi-
nation of nevus cells may also play a
role in nevus involution (Kantor and
Wheeland, 1987). The nevus cells in
the epidermis or in the superficial
dermis are more likely to be larger
and express melanocytic differentiation
antigens compared with the deeper
cells consistent with developmental
models. A similar antigen expression
pattern is seen in acquired nevi.
Although there is consensus that
congenital nevi grow along develop-
mental pathways toward the epidermis,
for acquired nevi there is an active
debate as to the direction of migration.
Unna described the process of Abtrop-
fung, the dropping off of melanocytic
cells into the dermis from the epider-
mis; whereas Cramer (1991) has pro-
posed the process of Hochsteigerung,
migration toward the epidermis. He
proposes that the precursor cells are
associated with nerve tips and that
there are four discrete migration/differ-
entiation stages that may be involved
in normal melanocytic turnover, nevus,
and melanoma formation (Cramer,
1984).
One of the ways to determine the
direction of growth is to evaluate nevi
as they develop. The majority of the
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nevi removed from children clearly
include a dermal component (Worret
and Burgdorf, 1998). Dermoscopically,
nevi developing in children often have
a globular pattern, which is also most
consistent with nevi that include a
dermal component (Zalaudek et al.,
2006). Thus, if these nevi do not evolve
in the dermis, dermal migration from
the epidermis must be a very early
process.
In our own studies on early growing
melanocytic neoplasms, utilizing only
the residual tissue in the block, an
obvious dermal component was detect-
able in 58% of the lesions, Ki67þ cells
were rare but could be identified in the
dermal component, and upwardly
mobile ‘‘pagetoid’’ cells could be
identified in 32% of the growing
lesions (Molino et al., 2003). Large
junctional nests (475% of the epider-
mal thickness) were present in 42% of
the lesions, and some of these nests
were clearly being expelled through
the epidermis (Figure 3). These findings
were consistent with dermal origin
and epidermal migration. Given the
presence of pagetoid cells in growing
nevi, we need to be careful not to
overinterpret growing benign nevi as
melanoma. Ever improving surface
microscopic technologies, such as con-
focal, will be able to give us a clearer
picture as to the features to expect
during normal nevus growth.
The direction of melanocyte migra-
tion has been evaluated in skin grafts.
It has been demonstrated that KIT-
activated melanocytic cells injected
into the dermis of a graft migrate into
the epidermis (Alexeev and Yoon,
2006; Grichnik, 2006b). This ability of
melanocytic cells to migrate could also
explain how nevus cells washed into a
lymph node could migrate into the
lymph node’s capsule. Although devel-
opmentally this direction of migration
makes sense, it is important to point out
that experiments with transformed cul-
tured melanocytes have demonstrated
that these cells can penetrate into the
dermal component of the graft (Chud-
novsky et al., 2005); therefore, migra-
tion from the epidermis into the dermis
is also possible.
The direction of melanocytic migra-
tion during nevus development will
eventually be definitively determined
through sequential imaging. Confocal
microscopy and optical coherence to-
mography are likely to play critical
roles in defining this process. Dermo-
scopy may also provide information
based on color features. Owing to light
scattering, blue coloration represents
dermal melanin. Both decreasing blue
features suggesting upward growth
and increasing blue features suggesting
downward growth have been noted
(Pizzichetta et al., 2006; Zalaudek
et al., 2007). However, because ame-
lanotic cells in the dermis could
become more pigmented as they ma-
ture, increasing blue pigmentation does
not necessarily reflect migration into
a b
dc
Figure 3. Growing melanocytic neoplasms have features suggesting epidermal tumor loss and dermal
proliferation. Growing melanocytic neoplasms can be detected clinically (a) by comparing the patient’s
lesion on a follow-up visit (lower left panel) with photographs from a prior visit (upper left panel).
This particular lesion was approximately 5mm in longest diameter (inset) and was pathologically
interpreted as an atypical (dysplastic) nevus with severe atypia. In growing melanocytic neoplasms,
melanocytic cells could be detected in the upper layers of the epidermis and in the stratum corneum
(b, arrows, size bar¼ 100mm). In other lesions, melanocytic nests of cells could be identified in the
stratum corneum (c, arrow, size bar¼ 100mm) and proliferating dermal cells could be identified with
immunohistochemical staining (red) for Ki67 (d, arrow, size bar¼ 200mm, 50 mm (inset)).
Figure 2. Pagetoid melanocytic cells in congenital nevus. Photomicrograph of hematoxylin and
eosin-stained section of a congenital melanocytic nevus excised from the left buttock of a 10-month-old
female child. Two pagetoid melanocytes are clearly visualized in the mid-spinous and granular layers
of the epidermis (black arrows).
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the dermis, and thus further studies will
be required. Beyond just direction,
these imaging techniques will allow
further study into the melanocytic
developmental process. There are
many different patterns of nevi, and
theoretically, the growth pattern should
be a reflection of the underlying muta-
tion and the local environmental influ-
ences on cell growth and survival
(Figure 4). B-Raf and N-Ras mutations
have been associated with acquired
nevi but specific dermoscopic patterns
have yet to be delineated.
B-Raf-activating mutations are com-
monly seen in acquired nevi and N-Ras
mutations are commonly seen in con-
genital nevi (Ichii-Nakato et al., 2006;
Bauer et al., 2007). N-Ras not only
activates a number of pathways, inclu-
ding phosphoinositide 3 kinase and
Ral, but also activates B-Raf, leading
to a common activation of downstream
mitogen activated protein kinase and
ERK pathways (Arbiser, 2003), redu-
cing the need for stimulatory cytokines.
In culture, nevus cells are also less
dependent on growth factors when
compared with normal melanocytes
(Mancianti et al., 1993; Alanko et al.,
1999). This suggests that although the
underlying mutations are not sufficient
to drive malignancy, they are sufficient
to allow some independence from the
normal homeostatic mechanisms.
Thus, nevi develop due to mutations
in a precursor cell that activate prolif-
erative pathways, or suppress apoptotic
pathways, allowing for the accumula-
tion of melanocytic cells in the skin.
The specific pattern of this accumula-
tion is anticipated to be a reflection of
the underlying mutation in the precur-
sor cell. The direction of nevus growth
is still in debate; however, similar to
congenital nevi, it is reasonable to
assume that acquired melanocytic nevi
(with a dermal component) develop
from a mutant dermal precursor and
migrate and differentiate along normal
melanocytic developmental pathways
toward the epidermis. Once in the
epidermis, there may be an increased
proliferative response due to local
growth factors and excess melano-
cytic cells would be shed through the
stratum corneum.
Melanoma
Role of nevi in melanoma develop-
ment. The development of melanoma
has been modeled as a stepwise process
from a cutaneous melanocyte through
nevus and dysplastic nevus stages to in
situ and eventually invasive melanoma.
However, approximately three-fourths of
melanomas develop in normal skin and
less than one-half of the nevi associated
with melanoma are dysplastic (Bevona
et al., 2003). Thus, it is not clear that a
dysplastic nevus is really any more likely
to develop a melanoma than any other
type of nevus, and further it is quite clear
that a nevus precursor is not required for



















Figure 4. Melanocytic neoplasm growth patterns. Melanocytic neoplasm demonstrate numerous different repeatable patterns on patient’s skin surface.
Presumably, each of distinct patterns represents an underlying distinct mutation, developmental phase, or local signaling environment. Repeatable distinct
patterns can be noted for acquired nevi (common and dysplastic), Spitz nevi, ‘‘congenital’’ nevi, lentigines, Reed nevi, blue nevi, and combined blue nevi.
Furthermore, distinct patterns can be noted for different melanoma types, indicated here in the red boxes, superficial spreading, lentigo maligna, acral lentiginous,
and others. Theoretically, these lesions could be derived from a common precursor (brown oval) that follows normal developmental pathways to the epidermis.
Dependent on the mutation and local environmental factors, the neoplasm would expand and migrate in the dermal and the epidermal compartments.
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nomenon is difficult to explain utilizing
current dogma. However, it is relatively
straightforward to explain based on the
stem cell theory. Melanoma could de-
velop directly from a quiescent precur-
sor cell that had accumulated a
malignant complement of mutations.
The one-fourth of melanomas associated
with nevi may be due to a secon-
dary mutation developing in a growing
stem cell population giving rise to a
benign nevus.
Increased mole burden clearly in-
creases melanoma risk. For patients
with large congenital nevi, the mela-
noma risk appears to be correlated with
the volume of the nevus and malignant
transformation often appears to occur
within the nevus at a young age
(Krengel et al., 2006). For patients with
numerous acquired nevi, the bulk of
the risk may be in the otherwise normal
appearing skin. It is not clear what
drives this risk but there are a number
of possibilities. First, the patient’s nevus
precursor (stem) cells may be increased
in number, have had increased expo-
sure to mutagenic events, or increased
sensitivity to mutagenic events. Second,
the patient may have less effective
immunosurveillance (or other mechan-
isms) to inhibit the growth of melano-
mas and/or nevi from the mutant
precursor cells. Finally, the precursor
cells may have an inherent increase in
self-renewal capacity, leading to an
increased window of time for muta-
tions to occur. Interestingly, it has been
noted that the telomeres are longer in
the white blood cells of patients with
numerous nevi (Bataille et al., 2007),
suggesting increased longevity and
proliferative potential.
Another interesting issue is differ-
ence in age for nevus versus melanoma
development. Most nevi develop dur-
ing late childhood and early adulthood,
whereas melanoma incidence con-
tinues to increase in the later years of
life (Banky et al., 2005). It is not clear
what drives this phenomenon but there
are a number of possibilities. First, the
longer the period the precursor (stem)
cell remains quiescent, the more the
mutations it may accumulate, resulting
in a greater chance for malignancy.
Second, mutant stem cells with anti-
apoptotic mechanisms may be retained
and expanded with age. Additional
mutations in these cells would be more
likely to create a malignancy. Third,
melanomas that are slow growing may
simply be easier to detect at older ages.
Fourth, as the patient ages, they may
lose effective immunosurveillance (or
other mechanism) for inhibiting the
growth of melanoma. Finally, it is
possible that somehow the body re-
cruits normal stem cells first and only
later relies on the mutated stem cells.
Thus, there is a clear association of
nevi with melanoma risk. Some of this
risk is due to the potential for second-
ary mutations within nevi. However,
the majority of the risk may be due to
the inherent properties of the stem cell
population in individuals with numer-
ous moles.
Origin and direction of malignant
melanoma growth. Similar to acquired
nevi, the traditional model suggests that
melanomas initially develop in the
epidermis and then invade the dermis.
This is largely based on pathologic
features in which the lowest risk in situ
melanoma tumors are noted to be
present entirely in the epidermis,
whereas high-risk tumors are present in
deeper dermal tissues. Thus, it is reas-
onable to assume based on progression
models that the tumor must first arise in
the epidermis. These models also sug-
gest that the cell of origin for the tumor
is the epidermal melanocyte. This is
also supported by research that reveals
that melanocytes can be transformed
with oncogenes and acquire malignant/
invasive characteristics (Chudnovsky
et al., 2005). Furthermore, the tyrosi-
nase promoter, expressed in melano-
cytes, has been shown to induce
melanoma when driving oncogenic
proteins SV40E (Kelsall and Mintz,
1998) and N-Ras (Wong and Chin,
2000). Thus, it is possible to generate
a melanoma from a cell expressing
melanocytic proteins. The extent to
which these melanocytes are fully
differentiated and the degree of plasti-
city maintained in the cell undergoing
the transformation event have yet to be
fully clarified.
The stem cell model is essentially the
converse of the traditional model.
Although it does not rule out epidermal
evolution of melanoma, which could
very well be the case especially for
lentigo maligna, it favors migration to
the epidermis from a dermal precursor.
In this model, low-risk, in situ or thin
invasive, melanomas would be highly
attracted to the epidermis and migrate
toward this location and thus minimizing
spread from the tissue. As additional
mutations accumulated in the tumor
(due to genomic instability), the melano-
ma cells would become less growth
factor-dependent and gain an increased
capacity to grow in deeper levels of the
dermis and other tissues. It is important
to note that on review of in situ
tumors, 29% were found to have an
intradermal component (Megahed et al.,
2002), so it is not entirely inconceivable
that many of these tumors have a dermal
derivation. As the dermal TSC accumu-
lated more mutations, the capacity to
produce cells that could continue to
differentiate along normal melanocytic
pathways would be reduced, giving the
impression of dedifferentiation when
actually it would be due to the unmask-
ing of the immature malignant stem cell
population.
Although early melanomas are diffi-
cult to grow in culture, a significant
proportion of metastatic melanomas
can grow readily in culture without
the need to add exogenous growth
factors (Halaban et al., 1986). A few
melanomas do exist that have KIT-
activating mutations and, therefore,
may be sensitive to KIT-inhibiting
agents (Curtin et al., 2006), but most
have downregulated this pathway pre-
sumably because its homeostatic role
could be detrimental to the viability of
the tumor. Inhibition of the ET-3/
endothelin B receptor pathway has
been reported to inhibit the growth of
melanoma lines (Lahav et al., 1999).
However, for the most part, melanomas
are largely growth factor-independent,
presumably due to mutations, such as
N-Ras activation or B-Raf/PTEN, that
promote proliferation and survival
(Tsao et al., 2004) or from autocrine
signaling loops due to activation of
pathways leading to the production of
their own growth factors. This inde-
pendence from homeostatic pathways
allows the tumors to thrive in non-
epidermal environments.
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Thus, at this point, whether melano-
mas develop in the epidermis and
migrate into the dermis or develop in
the dermis with migration to the
epidermis is still a matter of debate.
However, in either scenario, the deeper
the tumor in the dermal tissue, the
lower the requirement for epidermal
factors and the greater the risk that
tumor will be able to proliferate outside
of the skin surface and be potentially
deadly.
Stem cell/developmental behavior.
Regardless of origin, it is clear that a
subpopulation of TSCs exist in melano-
mas (Figure 5). Studies on metastatic
melanoma lines have revealed that the
cultures are heterogeneous even when
derived from a single cell (Grichnik
et al., 2006). The different cell popula-
tions within these cultures appear to
have diverse characteristics. A small-
cell phenotype has been noted that
appears to enter the cell cycle at a
lower rate but has an increased capa-
city to expand the culture. The small
cells had the capacity to give rise
to larger, more proliferative cells
(TA cells). The TA cells then eventually
gave rise to still larger, more melanized
cells. Furthermore, some of the
larger, more melanized cells appeared
to have terminally differentiated and
were eventually lost from culture.
These experiments suggested a general
forward developmental flow of the
process. However, even after double
cell flow purification of the larger cell
forms, some small cell forms reap-
peared in culture. This could have
been due to incomplete purification,
but it could also be due to the
possibility that some of the TA cells
were able to re-occupy the stem cell
niche, reverting to a small-cell pheno-
type. Thus, this suggests that there may
also be a degree of backward flow
in the culture system to achieve the
appropriate embryonic developmental
balance. It is also important to note that
the small cell forms were very weakly
adherent and were readily released
from the plate with simple media
removal. Despite being relatively free
floating, these cells were very effective
at establishing new cultures. Tumor
spheroids reminiscent of those
described for stem cells also readily
developed under dense culture condi-
tions. A small subpopulation of nestin
(pluripotent stem cell marker)-positive
cells could be identified in dense
melanoma cultures, suggesting the pre-
sence of a stem cell phenotype.
Other groups have also identified
potential TSC markers. Fang et al.
(2005) noted that non-adherent spher-
oids developed in approximately 20%
of melanomas cultured in ESC media.
Cells from these spheroids could be
differentiated into melanocytic, adipo-
cytic, osteocytic, and chondrocytic
lineages. Compared with the adherent
cells, the spheroid cells were more
tumorgenic in animal models. The
non-adherent spheroid cells were found
to include CD20 B-cell markers. The
sorted CD20 fraction were found to be
more spheroidogenic (more likely to
make sphere or make larger spheres),
and had more potential for mesenchy-
mal differentiation. The CD20 marker
was also noted to be present in approxi-
mately 20% of human metastatic mela-
nomas by immunohistochemisty.
A second group has identified
ABCB5 in melanomas (tissue sample
and in cell lines) as preferentially
marking a subset of CD133þ -expres-
sing cells in melanomas (Frank et al.,
2005). The ABCB5þ cells were also
CD166þ . Inhibition of the ABCB5
pump significantly reversed resistance
to doxorubicin. Cells double labeling
for ABCB5 and CD133 were approxi-
mately 2% of the G3361 line. These
markers also stained melanoma tissue
samples (positive in all tissue sam-
ples—overall staining in each sample
o50% six tumors examined).
A third group has reported that
CD166, CD133, and nestin are immu-
nohistochemically expressed at signi-
ficantly higher levels in melanoma
compared with banal nevi (Klein
et al., 2007). Further, nestin was found
to be significantly increased in meta-
static melanoma compared with pri-
mary melanoma.
A fourth group has specifically iso-
lated CD133þ cells from human mel-
anomas (Monzani et al., 2007). This
group noted that the CD133þ cells
were present at levels ranging from 0.2
to 0.8% of the total cells in seven
melanoma specimens. The CD133þ
melanoma cells all grew tumors in
NOD-SCID mice whereas CD133
melanoma cells failed to grow.
Melanoma cultures are quite dyna-
mic and antigen expression can be
erratic. In our hands, the greatest
degree of heterogeneity exists in long-
term dense cultures with partial but
frequent media changes (Grichnik
et al., 2006). We have noted waves of
patterning between nestin and KIT
a b
c d
Figure 5. Metastatic melanomas include cells with stem cell-like features. Some melanoma cultures
display a heterogeneous population of tumor cells, including small weakly adherent cells (a, line DM3N)
and larger adherent phenotypes (b, line DM3N). Although some of the larger cell phenotypes (b) do not
appear to be significantly proliferative, low-confluence cultures of the small weakly adherent cells
(a) have the capacity to perpetuate heterogeneous colonies in culture (c, line DM3N) while maintaining
a subpopulation of small weakly adherent cells (arrow). Melanoma line DM1N (d) plated at low
confluence also give rise to heterogeneous colonies after transfer as well as maintaining a subpopulation
of small weakly adherent cells (arrows). Magnification is the same for all photos; size bar¼200 mm.
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(Figure 6) as well as the presence of
neuronal appearing melanoma cells
with dendrites reaching into tumor
spheroids (Figure 6). We hypothesize
that this is due to enhanced cell-to-cell
and cell-to-matrix microenvironments
as would be expected during normal
development. Matrix microenviron-
ment components have been shown
to promote endothelial differentiation
of melanoma cells (Hendrix et al.,
2003). Local environmental factors
have also been proposed to control
melanoma growth (Hendrix et al.,
2007; Lee and Herlyn, 2007).
Thus, melanomas are heterogeneous
and behave in a manner consistent
with a developmental system. Within
this mass of cells is a subpopulation of
cells with stem cell-like features. The
data support a tumor derivation from
a stem cell. The data from the
CD133 experiments clearly reinforce
arguments for a stem cell derivation
given the lack of tumorgenicity of
CD133-negative cells.
Genomic instability and concept of
meiomitosis. Melanomas, unlike benign
nevi, have markedly unstable genomes.
Large fragments of chromosomes are
often gained or lost (Bastian et al.,
2000; Stark and Hayward, 2007). DNA
repair pathways clearly play a role in
the development of melanoma and
other skin cancers as markedly demon-
strated in patients with xeroderma
pigmentosa (Kraemer et al., 1994). It
is quite possible that these DNA repair
mechanisms lead to significant geno-
mic instability (Charames and Bapat,
2003). Another process that has been
speculated to cause genomic instability
is telomere crisis in which critically
shortened telomeres result in strand
breaks and chromosomal fusion (Gilley
et al., 2005). However, given the stem
cell biology and plasticity of mela-
noma, there is another area that needs
to be seriously considered: the collision
of two cellular division pathways,
meiosis and mitosis, resulting in marked
genomic instability (meiomitosis).
Meiosis is a cellular division path-
way in germ cells that promotes the
recombination of large expanses of
chromosomal DNA, potentially similar
in size to those lost or gained in
cancers. In meiosis, homologous chro-
mosomes are held together by cohe-
sions, and after resolution of chiasma
(the recombination crossover points
with the other chromosome pair), the
homologous chromosomes are segre-
gated together (Figure 7). In normal
mitosis, there are no chiasma and sister
chromatids are directly separated. In
meiomitosis, the mitotic cancer cells
would also have partially expressed
meiotic machinery. The presence of
chiasma, cohesins, and an aberrantly
assembled mitotic spindle would be
expected to result in significant shear-
ing and/or mis-segregation of DNA
sequences. Cells surviving this event
would likely be aneuploid. Melanoma
may be particularly prone to meiomi-
tosis given the high frequency of testis
antigen expression in the tumor cells,
77% for at least 1 of 6 antigens in mela-
noma, 0% in nevi (Luftl et al., 2004).
Two of the testis antigens expressed
in melanoma are known meiosis
proteins (Tureci et al., 1998; Chen
et al., 2005), supporting the possibility
that meiomitosis plays a role in geno-
mic instability.
Why would germ cell differentiation
be important to a tumor? The answer
may lie in self-renewal. No cell system
is better equipped than the germ cell
system to produce cells with an infinite
life span. The highest level of telomer-
ase in the adult is in the testis, and its
expression is highest in the primary
spermatocyte just prior to meiosis I, as
it gives rise to the secondary spermato-
cyte (Bekaert et al., 2004). Thus, tumor
cells differentiating along the germ cell
pathway may become immortal via
telomerase expression but at the cost
of meiosis protein expression and
genomic instability. It is also tempting
to speculate that the reason the germ
cell compartment is ‘‘privileged’’ is so
that if testis antigens are expressed in
cells outside the germ cell compart-
ment, they will be destroyed before the
cell has a significant chance to express
self-renewal and meiotic pathways
driving further tumor progression.
Genomic instability has been studied
in metastatic melanoma lesions in a
patient who survived with the disease
for an extended period of time (Wang
et al., 2006). The melanoma was found
to have a b-catenin mutation and that
specific mutation was present in all
subsequent metastases. However, karyo-
typing and genetic analysis revealed
marked genomic instability in each of
the metastasis and the pattern was
sufficiently different from metastasis to
metastasis (and from cell to cell in some
cultures), as to not be due to a linear
progression. These findings suggested
that the metastatically competent cell
was more genomically intact than the
a b
c
Figure 6. Melanoma cells displaying developmental pathways. Melanoma cells are dynamic and the
heterogeneous features of the cell population are best detected in long-term dense cultures, presumably
due to local microenvironments created by the tumor. Neuronal cells can be identified as shown here in
a GFP-positive melanoma cell after 4 months in culture (a). This cell is extending dendrites into two
tumor spheroids (white arrows). In the DM2N melanoma line, both KIT and the pluripotent neural
stem cell marker nestin are expressed. In this system, waves of nestin (FITC-stained, green) and KIT
(Cy3-stained, red) are expressed in developing spheroids (b) and sheets (c) of cells appearing similar
to those which would be anticipated during embryonic development.
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rest of the locally produced tumor
bulk (Grichnik, 2006a). Thus, ongoing
marked genomic instability might hin-
der the capacity of daughter cells to
successfully metastasize.
The stem cell characteristics of mel-
anoma and the expression of testis
antigens should lead us to consider the
potential role of germ cell differentiation
in enhancing self-renewal while creat-
ing genomic instability through meio-
mitosis. Given the destruction wreaked
upon the cell with genomic instability,
only a subpopulation of cells may
remain metastatically competent.
Melanoma stem cell progression model.
Melanoma progression and metastasis
is traditionally modeled as a stepwise
process with the initial mutagenic
event occurring in a melanocyte in
the epidermis, with further mutation
resulting in the proliferation passing
through nevus and dysplastic nevus
phases. The malignant cells eventually
acquire the ability to digest their way
through the basement membrane. Then
with additional mutations, the cells
acquire a migratory form and even-
tually physically penetrate the lympha-
tic vessel walls and travel to the local
lymph node where they remain trapped
until they expand sufficiently to popu-
late the next node in the chain.
There are a number of questions the
traditional model cannot readily explain.
These include: (1) If dermal invasion is a
second malignant step in melanoma
development, how do we write off the
fact that benign nevi readily ‘‘invade’’
the dermis? (2) If precursor nevus and
dysplastic nevus stages are critical, then
why do 75% of melanomas arise in
normal skin? (3) How can we explain
the fact that benign nevus cells can also
be found in lymph nodes? (4) If the
lymph node traps the tumor cells, why
does sentinel lymph biopsy and regional
lymph node dissection fail to improve
survival? (5) Why despite an exuberant
immunologic response to the primary
melanoma or to the vaccine therapy
does the immune system fail to eliminate
metastatic disease? And finally (6) How
can an aggressive tumor remain dormant
for decades and then reoccur?
The stem cell model (Figure 8) more
readily addresses many of these issues.
In contrast to the traditional theory of
melanoma derivation from a differen-
tiated melanocyte, the stem cell model
suggests that the initial mutations accu-
mulate in a quiescent stem cell. Even-
tually, environmental signaling would
activate the stem cell, but due to the
mutations, proliferation would not be
appropriately controlled. Benign tu-
mors would be growth restricted
whereas malignant tumors would not.
Secondary mutations could occur in
the expanding benign cells creating the
development of a melanoma within a
nevus, but the nevus step would not be
required. The neoplastic cells produced
would attempt to follow normal mela-
nocytic differentiation pathways in-
cluding migration into the epidermis.
In the epidermis, local growth factors
would likely drive further proliferation,
and the excess tumor cells would be
discharged through the epidermis into
the stratum corneum. The stem cell
component in the dermis would con-
tinue to expand, and some TSCs would
inappropriately express germ cell path-
ways not only allowing for increased
self-renewal but also driving genomic
instability due to meiomitosis. In the
malignant tumors, this would result in
different subclones of cells and would
display the potentially diagnostic non-
uniform surface features (Lucas et al.,
2003). Although lymph node metastasis
is often modeled as an active process, it
is important to recall that carbon and
tattoo ink can readily pass from the skin
to the lymph node. Some of the dermal
cells from both the benign and the
malignant tumors could be washed into
the lymph system. Thus, although more
adherent melanoma cells would bind in
the lymph node and possibly migrate
toward the capsule, the weakly adhe-
rent TSCs may pass straight through
the nodal chain and enter the circulatory
system. The small quiescent TSCs would
be overlooked by the immune system
and could continue to circulate long
term, but eventually would reinsert in
tissues in accordance with normal stem
cell regenerative pathways. These TSCs
would again activate when the environ-
mental signals where favorable and the
process would continue.
Treatment
Regardless of the model applied, it is
clear that melanomas are heteroge-
neous and include a distinct subpopu-
lation of TSCs. These TSCs may be
difficult to target with conventional
treatments, as they may lack significant
proliferation decreasing the effective-
ness of anti-proliferative agents, lack
significant antigen expression inhibit-
ing vaccine efforts, and may not be
Mitosis Meiosis Meiomitosis
Figure 7. Meiomitosis. During normal mitosis sister chromatids are separated into different cells. During
meiosis, homologous chromosomes are held together by cohesions (purple lines) and are segregated
together after resolution of chiasma (recombination crossover points) with the other chromosome pair.
A second cycle separates the sister chromatids. The term ‘‘meiomitosis’’ is used for mitotic cells, in which
meiotic machinery is partially expressed. In these cells, chiasma occur and sister chromatids are
partially linked together with cohesions. During cell division, the attempt to separate the sister
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dependent on a targetable mutated
pathway while in a quiescent state. In
addition, even if the TSCs were suscep-
tible to a particular agent, they may
have an enhanced ability to pump the
agent out of the cell minimizing its
effect (as noted with ATP binding
cassette transporters—Frank et al.,
2005). Furthermore, even if it was
possible to fully eradicate the TSCs, it
is also possible that some of the TA cells
could revert to TSCs, similar to that
noted in the murine melanocytic stem
cell experiments (Nishimura et al.,
2002). Thus, treatment of this hetero-
geneous population of melanoma cells
will be quite a challenge, requiring
eradication of the TSC subpopulation
as well as any cells capable of giving
rise to more TSCs. For the purpose of
discussion, we will consider the TA
cells, the only population with the
potential capacity to revert to a TSC
state, the term TSC/TAs will be used to
describe the tumorigenic cell population
within the entire heterogeneous popula-
tion of melanoma cells.
There are a number of treatment
approaches that may be considered for
the TSC/TAs. One approach would be to
activate the TSCs and differentiate the
entire TSC/TA population to a chemo-
therapy sensitive or non-proliferative cell
type. A second approach would be a
targeted multiantigenic approach against
the TSC/TA population either by activat-
ing the immune system or by utilizing
targeted reagent antibodies. It is possible
that targeting the CD133þ melanoma
cells in a specific manner will destroy all
TSC/TAs, but it is likely that additional
approaches will be required. A third
approach would be to target a specific
mutation or aberrantly activated path-
way within the TSC/TA population.
However, this therapy might only kill
the TAs in which it was active, and this
approach might need to be coupled with
a reagent activating the quiescent TSCs
to make them susceptible. A fourth
approach would be to force all the
TSC/TA cells into a quiescent state,
preventing further development of
downstream tumor. These patients
would require long-term suppressive
therapies.
Thus, TSCs have inherited a number
of protective properties that will make
them difficult to destroy. It is clear
that any potentially successful therapy
will need to find creative methods
to eradicate the TSC subpopulation as
well as eliminating any cells capable
of making TSCs (TAs).
CONCLUSION
Stem cells function to replenish termi-
nally differentiated cell populations in
adult tissues. It is these stem cells that
are the most likely source for cancers.
The ultimate stem cell, the fertilized
egg, can give rise to over a trillion cells
comprising numerous different cell
populations. A cancer stem cell poten-
tially has access to this same cellular
machinery. The pigmentary system
serves as an ideal model for the study
of developmental biology and the role
of stem cells in tumorigenesis. A
discrete series of developmental expo-
sures, in vivo or in vitro, can differen-
tiate stem cells toward the melanocytic
lineage. Certain mutations in stem
cells, such as B-Raf activation, may
drive melanocytic differentiation with-
out the need for external signaling
pathways. Both benign and malignant
melanocytic tumors develop directly
on the skin surface allowing for the
evaluation of early events. Through the
study of melanoma and nevus devel-
opment, it is likely we will be able to
better understand the early events and
the role of stem cell biology in tumori-
genesis.
Numerous studies have demon-
strated the existence of TSCs within

























Figure 8. Stem cell-based model of melanocytic neoplasia. In this model, stem cell lineage cells (1)
implant into the dermis (2). When necessary to replenish melanocytes in the epidermal compartment,
these cells (2) migrate and implant in the basal layer of the epidermis (3). The cells in the epidermis
proliferate and differentiate giving rise to mature melanocytes (4). Eventually, the mature melanocytes are
shed through the stratum corneum (5). Mutations could occur at any level, but for the tumors with a
dermal component, mutations would occur in the dermal cells (2). For tumors confined to the epidermis,
mutations could occur in the epidermal cells (3) or in a dermal cell (2) that completely migrated into the
epidermis. The mutated cells would attempt to follow normal differentiation pathways, including the
shedding of excess cells through the stratum corneum. Some mutations could also result in aberrant
dermal migration, including along nerves and blood vessels (6). Cells in the dermis could accumulate
additional mutations (7). If the initial stem cell included only mutation for a benign nevus, the additional
mutation could then result in a focus of melanoma within the nevus. If the original stem cell included a
complement of mutations to create a melanoma, then these additional mutations would create new
tumor subpopulations. Loose non-adherent cells (from benign or malignant process) could ‘‘wash’’ into
the lymph system (8). Some of these cells would stick in the lymph node and cells retaining migratory
pathways may migrate into the capsule. The non-adherent stem-like cells may pass through the lymph
node and circulate systemically (9) as a mutated stem-like cell (1). This cell could then under the
appropriate conditions re-enter the dermis (2) (or some other tissue) and reinitiate the process.
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sence of TSC in melanomas and the
presence of stem cell populations in
human skin, it is reasonable to assume
that the skin stem cells serve as the cells
of origin for melanoma development.
However, the specific stem cell type
involved in the transformation process
and its location in the skin remains
undefined. Although many of the stem
cell population studies have focused on
follicular stem cells, most melanomas
do not appear to have a follicular
origin. Given the normal developmen-
tal direction of migration, it seems
likely that invasive melanomas are
based on a stem cell within the dermis.
Nevi would also be based on this
dermal stem cell, and existence of blue
nevi (heavily pigmented melanocytic
neoplasm that originates in the dermis
without any epidermal or follicular
involvement) also supports a derivation
from a melanocytic stem cell present in
the dermis.
A promising marker for dermal stem
cells is CD133. CD133þ cells have
been shown to give rise to endothelial
cells (Gehling et al., 2000), mast cells
(Dahl et al., 2002), and neurons and
glial cells (Uchida et al., 2000). Adipo-
cytes, osteocytes, and chondrocytes
have also been generated (Tondreau
et al., 2005). Although melanocytes
have not yet been reported to differen-
tiate from this population, the presence
of CD133þ melanoma TSC is highly
suggestive. Therefore, it is possible
that different mutations in a CD133þ
stem cell could result in different tumor
types, including malignant melanoma,
benign nevi, hemangiomas, lipomas,
neurofibromas, and mastocytomas.
CD133þ cells have been noted to be
increased in circulation after trauma
(Liu et al., 2007). It is also feasible that
mutant (possibly B-Raf) CD133þ stem
cells could be mobilized from a
patient’s bone marrow due to their
immunosuppressed state, and present
in the skin as eruptive nevi. The fact
that only the CD133þ melanoma cells
are tumorigenic (Monzani et al., 2007)
supports the role of a stem cell-driven
process.
Although melanoma derivation from
a stem cell seems likely, the potential
role for dedifferentiation from a mela-
nocyte cannot be ruled out. Support for
a dedifferentiation process includes
that fact that melanized quail cells
can dedifferentiate into multipotent
stem cells (Real et al., 2006), onco-
genes added to cultured melanocytes
can create tumors (Chudnovsky et al.,
2005), and genes driven from the
tyrosinase promoter can give rise to
melanomas in transgenic mice
(Kelsall and Mintz, 1998; Wong and
Chin, 2000). Certainly, developmental
models include plasticity, allowing
neighboring cells to assume the func-
tion of cells lost during development.
Thus, normal developmental biology
does allow for both ‘‘stem cell’’ and
‘‘dedifferentiation/plasticity’’ mechan-
isms. At this point, it is reasonable
to assume that both mechanisms may
be at play to varying degrees in
melanoma.
Melanocytic tumors are probably
best viewed as a pliable developmental
system with a TSC component. These
tumors may be best defined by four
biologic parameters. The first para-
meter is the nature of the critical path-
way(s) that have been mutated in the
tumor cells. These pathway(s) are likely
to define the direction of cellular
differentiation as well as the regulation
over the proliferative and apoptotic
process. The second parameter is the
range of cell’s differentiation/plasticity
capacity. The extent of this capacity
may be, in part, defined by the mutated
pathway(s), but it may also be defined
by the state of differentiation (organiza-
tion of the nuclear matrix) in the cell of
origin. Theoretically, tumor origin in a
stem cell would allow for a far greater
range of differentiation/plasticity capa-
city. This capacity would allow cells to
better survive under different environ-
mental conditions and allow for greater
diversity in expression programs, such
as allowing germ cell pathway differen-
tiation, which may be advantageous
for the expression of telomerase but
hazardous due to the potential for
meiomitosis. The third parameter is
the intactness of the genome. Increas-
ing genomic instability will result in
the loss of primary DNA sequence
data. Surviving cells may benefit
initially from acceleration of certain
pathways but at the same time will
loose other potentially useful capabil-
ities. The fourth and final parameter
is telomere length. As telomeres short-
en, the cells ability to continue to
replicate is diminished. Thus, when
viewed as a pliable, but mutated,
developmental system, it may be ne-
cessary to consider these four different
facets in defining the neoplasm’s ulti-
mate behavior.
In summary, melanoma tumors,
similar to other solid cancers, clearly
include a subpopulation of TSCs. These
cells appear to have the unique capa-
city to perpetuate the tumor as well as
the capacity to differentiate along
different cellular developmental lines.
The melanocytic system is a model
system for normal and abnormal adult
tissue stem cell biology. The develop-
ment of these tumors on the skin
surface and the advance of skin surface
imaging technologies will help us to
study the complexities of the oncologic
process. The lessons learned will be
able to be applied across many solid
tumor types and will have ramifications
for tumor development, diagnosis,
prognosis, and treatment.
CONFLICT OF INTEREST
Founder and major shareholder—Digital Derm
Inc.—MoleMapCD (total body photography).
Consulting and Grants—Electro-Optical Sciences
Inc.—Melafind (melanoma detection device) and
Spectral Image Inc.—Dermatologic Diagnostics.
ACKNOWLEDGMENTS
Division of Dermatology and the Benefactors to
the Duke Comprehensive Cancer center, espe-
cially Fred and Sharon Matt (in honor of James
Matt), Carolyn Holding, Carmen Ames, and
Rebecca Hundley for their generous financial
support, Harold Rabinovitz for his image of the
melanoma with blue features, and KP Grichnik,
KK Hipp, and JA Burch for their editorial review.
REFERENCES
Alanko T, Rosenberg M, Saksela O (1999) FGF
expression allows nevus cells to survive in
three-dimensional collagen gel under condi-
tions that induce apoptosis in normal human
melanocytes. J Invest Dermatol 113:111–6
Alexeev V, Yoon K (2006) Distinctive role of the
cKit receptor tyrosine kinase signaling in
mammalian melanocytes. J Invest Dermatol
126:1102–10
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ, Clarke MF (2003) Prospective
identification of tumorigenic breast cancer
cells. Proc Natl Acad Sci USA 100:3983–8
Amoh Y, Li L, Katsuoka K, Penman S, Hoffman
RM (2005) Multipotent nestin-positive,
www.jidonline.org 2377
JM Grichnik
Melanoma, Nevogenesis, and Stem Cell Biology
keratin-negative hair-follicle bulge stem cells
can form neurons. Proc Natl Acad Sci USA
102:5530–4
Arbiser JL (2003) Activation of B-raf in non-
malignant nevi predicts a novel tumor
suppressor gene in melanoma (MAP kinase
phosphatase). J Invest Dermatol 121:xiv
Banky JP, Kelly JW, English DR, Yeatman JM,
Dowling JP (2005) Incidence of new and
changed nevi and melanomas detected using
baseline images and dermoscopy in patients
at high risk for melanoma. Arch Dermatol
141:998–1006
Bastian BC, Kashani-Sabet M, HammH, Godfrey T,
Moore DH II, Brocker EB et al. (2000)
Gene amplifications characterize acral mela-
noma and permit the detection of occult
tumor cells in the surrounding skin. Cancer
Res 60:1968–73
Bataille V, Kato BS, Falchi M, Gardner J, Kimura
M, Lens M et al. (2007) Nevus size and
number are associated with telomere length
and represent potential markers of a decrea-
sed senescence in vivo. Cancer Epidemiol
Biomarkers Prev 16:1499–502
Bauer J, Curtin JA, Pinkel D, Bastian BC (2007)
Congenital melanocytic nevi frequently har-
bor NRAS mutations but no BRAF mutations.
J Invest Dermatol 127:179–82
Baynash AG, Hosoda K, Giaid A, Richardson JA,
Emoto N, Hammer RE et al. (1994) Inter-
action of endothelin-3 with endothelin-B
receptor is essential for development of
epidermal melanocytes and enteric neurons.
Cell 79:1277–85
Bekaert S, Derradji H, Baatout S (2004) Telomere
biology in mammalian germ cells and during
development. Dev Biol 274:15–30
Belicchi M, Pisati F, Lopa R, Porretti L, Fortunato
F, Sironi M et al. (2004) Human skin-derived
stem cells migrate throughout forebrain and
differentiate into astrocytes after injection
into adult mouse brain. J Neurosci Res 77:
475–86
Bennett DC, Medrano EE (2002) Molecular
regulation of melanocyte senescence.
Pigment Cell Res 15:242–50
Bevona C, Goggins W, Quinn T, Fullerton J,
Tsao H (2003) Cutaneous melanomas asso-
ciated with nevi. Arch Dermatol 139:1620–4
Bickenbach JR, Grinnell KL (2004) Epidermal
stem cells: interactions in developmental
environments. Differentiation 72:371–80
Blanpain C, Fuchs E (2006) Epidermal stem cells of
the skin. Annu Rev Cell Dev Biol 22:339–73
Bonnet D, Dick JE (1997) Human acute myeloid
leukemia is organized as a hierarchy that
originates from a primitive hematopoietic
cell. Nat Med 3:730–7
Botchkareva NV, Khlgatian M, Longley BJ,
Botchkarev VA, Gilchrest BA (2001) SCF/
c-kit signaling is required for cyclic regene-
ration of the hair pigmentation unit. FASEB J
15:645–58
Burkhart CG, Burkhart CN (2005) The mole
theory: primary function of melanocytes
and melanin may be antimicrobial defense
and immunomodulation (not solar protec-
tion). Int J Dermatol 44:340–2
Charames GS, Bapat B (2003) Genomic instability
and cancer. Curr Mol Med 3:589–96
Chen YT, Venditti CA, Theiler G, Stevenson BJ,
Iseli C, Gure AO et al. (2005) Identifi-
cation of CT46/HORMAD1, an immuno-
genic cancer/testis antigen encoding a
putative meiosis-related protein. Cancer
Immun 5:9
Chudnovsky Y, Adams AE, Robbins PB, Lin Q,
Khavari PA (2005) Use of human tissue to
assess the oncogenic activity of melanoma-
associated mutations. Nat Genet 37:745–9
Cotsarelis G (2006) Epithelial stem cells: a
folliculocentric view. J Invest Dermatol 126:
1459–68
Cramer SF (1984) The histogenesis of acquired
melanocytic nevi. Based on a new concept
of melanocytic differentiation. Am J Derma-
topathol 6:289–98
Cramer SF (1991) The origin of epidermal
melanocytes. Implications for the histogen-
esis of nevi and melanomas. Arch Pathol Lab
Med 115:115–9
Curtin JA, Busam K, Pinkel D, Bastian BC (2006)
Somatic activation of KIT in distinct subtypes
of melanoma. J Clin Oncol 24:4340–6
Dahl C, Saito H, Nielsen HV, Schiotz PO (2002)
The establishment of a combined serum-free
and serum-supplemented culture method of
obtaining functional cord blood-derived
human mast cells. J Immunol Methods 262:
137–43
Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho
RW et al. (2007) Phenotypic characterization
of human colorectal cancer stem cells. Proc
Natl Acad Sci USA 104:10158–63
de Cholnoky T (1941) Malignant Melanoma: A
clinical study of one hundred seventeen
cases. Ann Surg 113:392–410
Dupin E, Calloni G, Real C, Goncalves-Trentin A,
Le Douarin NM (2007) Neural crest progeni-
tors and stem cells. C R Biol 330:521–9
Etienne G, Cony-Makhoul P, Mahon FX (2002)
Imatinib mesylate and gray hair. N Engl J
Med 347:446
Ewing J (1930) The Problems of Melanoma. B J
Med 11:852–6
Fang D, Leishear K, Nguyen TK, Finko R, Cai K,
Fukunaga M et al. (2006) Defining the
conditions for the generation of melanocytes
from human embryonic stem cells. Stem
Cells 24:1668–77
Fang D, Nguyen TK, Leishear K, Finko R, Kulp
AN, Hotz S et al. (2005) A tumorigenic
subpopulation with stem cell properties in
melanomas. Cancer Res 65:9328–37
Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ,
Tohidian N, Meyskens FL Jr (2003) Melanin
as a target for melanoma chemotherapy: pro-
oxidant effect of oxygen and metals on
melanoma viability. Pigment Cell Res 16:
273–9
Fernandes KJ, McKenzie IA, Mill P, Smith KM,
Akhavan M, Barnabe-Heider F et al. (2004) A
dermal niche for multipotent adult skin-
derived precursor cells. Nat Cell Biol
6:1082–93
Frank NY, Margaryan A, Huang Y, Schatton T,
Waaga-Gasser AM, Gasser M et al. (2005)
ABCB5-mediated doxorubicin transport and
chemoresistance in human malignant mela-
noma. Cancer Res 65:4320–33
Frank NY, Pendse SS, Lapchak PH, Margaryan A,
Shlain D, Doeing C et al. (2003) Regulation
of progenitor cell fusion by ABCB5 P-
glycoprotein, a novel human ATP-binding
cassette transporter. J Biol Chem 278:
47156–65
Gehling UM, Ergun S, Schumacher U, Wagener
C, Pantel K, Otte M et al. (2000) In vitro
differentiation of endothelial cells from
AC133-positive progenitor cells. Blood
95:3106–12
Gilley D, Tanaka H, Herbert BS (2005) Telomere
dysfunction in aging and cancer. Int J
Biochem Cell Biol 37:1000–13
Grichnik JM (2006a) Genomic instability and
tumor stem cells. J Invest Dermatol 126:
1214–6
Grichnik JM (2006b) Kit and melanocyte migra-
tion. J Invest Dermatol 126:945–7
Grichnik JM, Ali WN, Burch JA, Byers JD, Garcia
CA, Clark RE et al. (1996) KIT expression
reveals a population of precursor melano-
cytes in human skin. J Invest Dermatol
106:967–71
Grichnik JM, Burch JA, Burchette J, Shea CR
(1998) The SCF/KIT pathway plays a critical
role in the control of normal human mela-
nocyte homeostasis. J Invest Dermatol
111:233–8
Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu
J, Darrow TL et al. (2006) Melanoma, a
tumor based on a mutant stem cell? J Invest
Dermatol 126:142–53
Grichnik JM, Crawford J, Jimenez F, Kurtzberg J,
Buchanan M, Blackwell S et al. (1995)
Human recombinant stem-cell factor in-
duces melanocytic hyperplasia in suscepti-
ble patients. J Am Acad Dermatol 33:577–83
Halaban R (2000) The regulation of normal melano-
cyte proliferation. Pigment Cell Res 13:4–14
Halaban R, Ghosh S, Duray P, Kirkwood JM,
Lerner AB (1986) Human melanocytes cul-
tured from nevi and melanomas. J Invest
Dermatol 87:95–101
Hardy K, Martin KL, Leese HJ, Winston RM,
Handyside AH (1990) Human preimplanta-
tion development in vitro is not adversely
affected by biopsy at the 8-cell stage. Hum
Reprod 5:708–14
Hendrix MJ, Seftor EA, Hess AR, Seftor RE (2003)
Vasculogenic mimicry and tumour-cell plas-
ticity: lessons from melanoma. Nat Rev
Cancer 3:411–21
Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-
Kulesa J, Kulesa PM, Postovit LM (2007)
Reprogramming metastatic tumour cells with
embryonic microenvironments. Nat Rev
Cancer 7:246–55
Hirobe T (2005) Role of keratinocyte-derived
factors involved in regulating the proli-
feration and differentiation of mammalian
2378 Journal of Investigative Dermatology (2008), Volume 128
JM Grichnik
Melanoma, Nevogenesis, and Stem Cell Biology
epidermal melanocytes. Pigment Cell Res
18:2–12
Ho MM, Ng AV, Lam S, Hung JY (2007) Side
population in human lung cancer cell lines
and tumors is enriched with stem-like cancer
cells. Cancer Res 67:4827–33
Hong L, Simon JD (2007) Current understanding
of the binding sites, capacity, affinity, and
biological significance of metals in melanin.
J Phys Chem B 111:7938–47
Hosoda K, Hammer RE, Richardson JA, Baynash
AG, Cheung JC, Giaid A et al. (1994)
Targeted and natural (piebald-lethal) muta-
tions of endothelin-B receptor gene produce
megacolon associated with spotted coat
color in mice. Cell 79:1267–76
Hu YF, Zhang ZJ, Sieber-Blum M (2006) An
epidermal neural crest stem cell (EPI-NCSC)
molecular signature. Stem Cells 24:2692–702
Hui P, Perkins A, Glusac E (2001) Assessment of
clonality in melanocytic nevi. J Cutan Pathol
28:140–4
Ichii-Nakato N, Takata M, Takayanagi S, Takashi-
ma S, Lin J, Murata H et al. (2006) High
frequency of BRAFV600E mutation in ac-
quired nevi and small congenital nevi, but
low frequency of mutation in medium-sized
congenital nevi. J Invest Dermatol 126:2111–8
Jiao Z, Zhang ZG, Hornyak TJ, Hozeska A, Zhang
RL, Wang Y et al. (2006) Dopachrome
tautomerase (Dct) regulates neural progeni-
tor cell proliferation. Dev Biol 296:396–408
Kantor GR, Wheeland RG (1987) Transepidermal
elimination of nevus cells. A possible me-
chanism of nevus involution. Arch Dermatol
123:1371–4
Kavak A, Akcan Y, Korkmaz U (2005) Hair
repigmentation in a hepatitis C patient
treated with interferon and ribavirin.Dermato-
logy 211:171–2
Kelsall SR, Mintz B (1998) Metastatic cutaneous
melanoma promoted by ultraviolet radiation
in mice with transgene-initiated low
melanoma susceptibility. Cancer Res 58:
4061–5
Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto
AJ, Tahan SR (2007) Increased expression of
stem cell markers in malignant melanoma.
Mod Pathol 20:102–7
Kondo T, Setoguchi T, Taga T (2004) Persistence
of a small subpopulation of cancer stem-like
cells in the C6 glioma cell line. Proc Natl
Acad Sci USA 101:781–6
Kraemer KH, Lee MM, Andrews AD, Lambert WC
(1994) The role of sunlight and DNA repair
in melanoma and nonmelanoma skin can-
cer. The xeroderma pigmentosum paradigm.
Arch Dermatol 130:1018–21
Krengel S, Hauschild A, Schafer T (2006) Mela-
noma risk in congenital melanocytic naevi:
a systematic review. Br J Dermatol 155:1–8
Kumamoto T, Shalhevet D, Matsue H, Mummert
ME, Ward BR, Jester JV et al. (2003) Hair
follicles serve as local reservoirs of skin mast
cell precursors. Blood 102:1654–60
Kunisada T, Lu SZ, Yoshida H, Nishikawa S,
Nishikawa S, Mizoguchi M et al. (1998)
Murine cutaneous mastocytosis and epider-
mal melanocytosis induced by keratinocyte
expression of transgenic stem cell factor.
J Exp Med 187:1565–73
Lahav R, Heffner G, Patterson PH (1999) An
endothelin receptor B antagonist inhibits
growth and induces cell death in human
melanoma cells in vitro and in vivo. Proc
Natl Acad Sci USA 96:11496–500
Lapidot T, Sirard C, Vormoor J, Murdoch B,
Hoang T, Caceres-Cortes J et al. (1994) A cell
initiating human acute myeloid leukaemia
after transplantation into SCID mice. Nature
367:645–8
Lee JT, Herlyn M (2007) Microenvironmental
influences in melanoma progression. J Cell
Biochem 101:862–72
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L,
Adsay V et al. (2007) Identification of pancrea-
tic cancer stem cells. Cancer Res 67:1030–7
Liang L, Bickenbach JR (2002) Somatic epidermal
stem cells can produce multiple cell lineages
during development. Stem Cells 20:21–31
Lin F, Burch JA, Singer S, Grichnik JM (2000) SCF
induced proliferation of human melanocytes
is masked in vitro by bFGF. J Invest Dermatol
114:859 (abstract)
Liu L, Liu H, Jao J, Liu H, Bergeron A, Dong JF
et al. (2007) Changes in circulating human
endothelial progenitor cells after brain
injury. J Neurotrauma 24:936–43
Lucas CR, Sanders LL, Murray JC, Myers SA, Hall
RP, Grichnik JM (2003) Early melanoma
detection: nonuniform dermoscopic features
and growth. J Am Acad Dermatol 48:663–71
Luftl M, Schuler G, Jungbluth AA (2004) Mela-
noma or not? Cancer testis antigens may
help. Br J Dermatol 151:1213–8
Mackenzie MA, Jordan SA, Budd PS, Jackson IJ
(1997) Activation of the receptor tyrosine
kinase Kit is required for the proliferation of
melanoblasts in the mouse embryo. Dev Biol
192:99–107
Mancianti ML, Gyorfi T, Shih IM, Valyi-Nagy I,
Levengood G, Menssen HD et al. (1993)
Growth regulation of cultured human nevus
cells. J Invest Dermatol 100:281S–7S
Megahed M, Schon M, Selimovic D, Schon MP
(2002) Reliability of diagnosis of melanoma
in situ. Lancet 359:1921–2
Meyskens Jr FL, Farmer PJ, Anton-Culver H (2004)
Etiologic pathogenesis of melanoma: a uni-
fying hypothesis for the missing attributable
risk. Clin Cancer Res 10:2581–3
Molino A, Lucas C, Benitez-Graham A, Burch JA,
Herman C, Selim A et al. (2003) Immature
dermal melanocytic cells are present in
growing melanocytic neoplasms. J Invest
Dermatol 121:1174 (abstract)
Monzani E, Facchetti F, Galmozzi E, Corsini E,
Benetti A, Cavazzin C et al. (2007) Melano-
ma contains CD133 and ABCG2 positive
cells with enhanced tumourigenic potential.
Eur J Cancer 43:935–46
Motohashi T, Aoki H, Chiba K, Yoshimura N,
Kunisada T (2007) Multipotent cell fate of
neural crest-like cells derived from embryo-
nic stem cells. Stem Cells 25:402–10
Na GY, Paek SH, Park BC, Kim DW, Lee WJ, Lee
SJ et al. (2006) Isolation and characterization
of outer root sheath melanocytes of human
hair follicles. Br J Dermatol 155:902–9
Nishikawa S, Kusakabe M, Yoshinaga K, Ogawa
M, Hayashi S, Kunisada T et al. (1991)
In utero manipulation of coat color forma-
tion by a monoclonal anti-c-kit antibody:
two distinct waves of c-kit-dependency
during melanocyte development. EMBO
J 10:2111–8
Nishikawa S, Osawa M (2007) Generating quies-
cent stem cells. Pigment Cell Res 20:263–70
Nishimura EK, Granter SR, Fisher DE (2005)
Mechanisms of hair graying: incomplete
melanocyte stem cell maintenance in the
niche. Science 307:720–4
Nishimura EK, Jordan SA, Oshima H, Yoshida H,
Osawa M, Moriyama M et al. (2002)
Dominant role of the niche in melanocyte
stem-cell fate determination. Nature 416:
854–60
Oback B, Wells DN (2007) Donor cell differ-
entiation, reprogramming, and cloning effi-
ciency: elusive or illusive correlation? Mol
Reprod Dev 74:646–54
O’Brien CA, Pollett A, Gallinger S, Dick JE (2007)
A human colon cancer cell capable of
initiating tumour growth in immunodeficient
mice. Nature 445:106–10
Okura M, Maeda H, Nishikawa S, Mizoguchi M
(1995) Effects of monoclonal anti-c-kit anti-
body (ACK2) on melanocytes in newborn
mice. J Invest Dermatol 105:322–8
Peters EM, Tobin DJ, Botchkareva N, Maurer M,
Paus R (2002) Migration of melanoblasts into
the developing murine hair follicle is accom-
panied by transient c-Kit expression.
J Histochem Cytochem 50:751–66
Petronic-Rosic V, Shea CR, Krausz T (2004)
Pagetoid melanocytosis: when is it signifi-
cant? Pathology (Phila) 36:435–44
Pharis DB, Zitelli JA (2001) Sunburn, trauma, and
the timing of biopsies of melanocytic nevi.
Dermatol Surg 27:835–6
Pierce KE, Michalopoulos J, Kiessling AA, Seibel
MM, Zilberstein M (1997) Preimplantation
development of mouse and human embryos
biopsied at cleavage stages using a modified
displacement technique. Hum Reprod
12:351–6
Pizzichetta MA, Massone C, Grandi G, Pelizzo G,
Soyer HP (2006) Morphologic changes of
acquired melanocytic nevi with eccentric
foci of hyperpigmentation (‘‘Bolognia sign’’)
assessed by dermoscopy. Arch Dermatol
142:479–83
Prince ME, Sivanandan R, Kaczorowski A, Wolf
GT, Kaplan MJ, Dalerba P et al. (2007)
Identification of a subpopulation of cells
with cancer stem cell properties in head and
neck squamous cell carcinoma. Proc Natl
Acad Sci USA 104:973–8
Real C, Glavieux-Pardanaud C, Le Douarin NM,
Dupin E (2006) Clonally cultured differen-
tiated pigment cells can dedifferentiate and
generate multipotent progenitors with self-
renewing potential. Dev Biol 300:656–69
www.jidonline.org 2379
JM Grichnik
Melanoma, Nevogenesis, and Stem Cell Biology
Reya T, Morrison SJ, Clarke MF, Weissman IL
(2001) Stem cells, cancer, and cancer stem
cells. Nature 414:105–11
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni
M, Todaro M, Peschle C et al. (2007)
Identification and expansion of human colon-
cancer-initiating cells. Nature 445:111–5
Robinson WA, Lemon M, Elefanty A, Harrison-
Smith M, Markham N, Norris D (1998)
Human acquired naevi are clonal. Melano-
ma Res 8:499–503
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J et al. (2003) Identifica-
tion of a cancer stem cell in human brain
tumors. Cancer Res 63:5821–8
Slominski A, Wortsman J, Tuckey RC, Paus R
(2007) Differential expression of HPA axis
homolog in the skin. Mol Cell Endocrinol
265–266:143–9
Stark M, Hayward N (2007) Genome-wide loss of
heterozygosity and copy number analysis in
melanoma using high-density single-nucleo-
tide polymorphism arrays. Cancer Res
67:2632–42
Takeda K, Takahashi NH, Shibahara S (2007)
Neuroendocrine functions of melanocytes:
beyond the skin-deep melanin maker. Toho-
ku J Exp Med 211:201–21
Tobin DJ, Hagen E, Botchkarev VA, Paus R (1998)
Do hair bulb melanocytes undergo apoptosis
during hair follicle regression (catagen)?
J Invest Dermatol 111:941–7
Toma JG, Akhavan M, Fernandes KJ, Barnabe-
Heider F, Sadikot A, Kaplan DR et al. (2001)
Isolation of multipotent adult stem cells from
the dermis of mammalian skin. Nat Cell Biol
3:778–84
Tondreau T, Meuleman N, Delforge A, Dejeneffe
M, Leroy R, Massy M et al. (2005) Mesen-
chymal stem cells derived from CD133-
positive cells in mobilized peripheral blood
and cord blood: proliferation, Oct4 expres-
sion, and plasticity. Stem Cells 23:1105–12
Tsao H, Goel V, Wu H, Yang G, Haluska FG
(2004) Genetic interaction between NRAS
and BRAF mutations and PTEN/MMAC1
inactivation in melanoma. J Invest Dermatol
122:337–41
Tumbar T, Guasch G, Greco V, Blanpain C,
Lowry WE, Rendl M et al. (2004) Defining
the epithelial stem cell niche in skin. Science
303:359–63
Tureci O, Sahin U, Zwick C, Koslowski M, Seitz
G, Pfreundschuh M (1998) Identification of
a meiosis-specific protein as a member of the
class of cancer/testis antigens. Proc Natl
Acad Sci USA 95:5211–6
Uchida N, Buck DW, He D, Reitsma MJ, Masek
M, Phan TV et al. (2000) Direct isolation of
human central nervous system stem cells.
Proc Natl Acad Sci USA 97:14720–5
Wang E, Voiculescu S, Le Poole IC, El-Gamil M,
Li X, Robbins PF et al. (2006) Clonal
persistence and evolution during a decade of
recurrent melanoma. J Invest Dermatol 126:
1372–7
Wilkie AL, Jordan SA, Jackson IJ (2002) Neural
crest progenitors of the melanocyte lineage:
coat colour patterns revisited. Development
129:3349–57
Wong AK, Chin L (2000) An inducible melanoma
model implicates a role for RAS in tumor
maintenance and angiogenesis. Cancer
Metastasis Rev 19:121–9
Wong CE, Paratore C, Dours-Zimmermann MT,
Rochat A, Pietri T, Suter U et al. (2006)
Neural crest-derived cells with stem cell
features can be traced back to multiple
lineages in the adult skin. J Cell Biol 175:
1005–15
Worret WI, Burgdorf WH (1998) Which direction
do nevus cells move? Abtropfung reexa-
mined. Am J Dermatopathol 20:135–9
Yamane T, Hayashi S, Mizoguchi M, Yamazaki H,
Kunisada T (1999) Derivation of melano-
cytes from embryonic stem cells in culture.
Dev Dyn 216:450–8
Yang CT, Johnson SL (2006) Small molecule-
induced ablation and subsequent regene-
ration of larval zebrafish melanocytes.
Development 133:3563–73
Yoshida H, Kunisada T, Kusakabe M, Nishikawa
S, Nishikawa SI (1996) Distinct stages
of melanocyte differentiation revealed by
analysis of nonuniform pigmentation pat-
terns. Development 122:1207–14
Yu H, Fang D, Kumar SM, Li L, Nguyen TK, Acs G
et al. (2006) Isolation of a novel population
of multipotent adult stem cells from human
hair follicles. Am J Pathol 168:1879–88
Yu Y, Flint A, Dvorin EL, Bischoff J (2002) AC133-
2, a novel isoform of human AC133 stem cell
antigen. J Biol Chem 277:20711–6
Zalaudek I, Ferrara G, Argenziano G (2007)
Dermoscopy insights into nevogenesis:
‘‘Abtropfung’’ vs ‘‘Hochsteigerung’’. Arch
Dermatol 143:284
Zalaudek I, Grinschgl S, Argenziano G, Marghoob
AA, Blum A, Richtig E et al. (2006) Age-
related prevalence of dermoscopy patterns in
acquired melanocytic naevi. Br J Dermatol
154:299–304
2380 Journal of Investigative Dermatology (2008), Volume 128
JM Grichnik
Melanoma, Nevogenesis, and Stem Cell Biology
